Literature DB >> 8607406

Signal-averaged P-wave duration and risk of paroxysmal atrial fibrillation in hyperthyroidism.

A Montereggi1, P Marconi, I Olivotto, G Castelli, A Dolara, M L Luisi, R G Gheri.   

Abstract

The onset of atrial fibrillation (AF) in hyperthyroid patients constitutes an unfavorable clinical event associated with high risk of cardiovascular complications, occurring in approximately one fifth of patients. Therefore, it is advantageous to define noninvasive markers that may identify patients at risk. The high-resolution, signal-averaged electrocardiogram was used to evaluate the relation between P-wave duration and occurrence of paroxysmal AF in a group of 50 patients with hyperthyroidism, of whom 24 had a history of paroxysmal AF and 26 did not. Filtered signal-averaged P-wave duration was measured over an average of 300 beats/patient while in sinus rhythm, both at the time of first diagnosis of hyperthyroidism and after restoration of euthyroidism by medical treatment. The 24 patients with paroxysmal AF had significantly greater P-wave duration than the 26 patients without it (135 +/- 7 vs 124 +/- 9 ms; p = 0.001). A P-wave duration cut-off value of 130 ms held specificity, sensitivity, and positive predictive accuracy values of 79%, 85%, and 83%, respectively. Of several variables, multivariate analysis showed P-wave duration to be the only independent variable significantly associated with the occurrence of paroxysmal AF. Thus, the high-resolution signal-averaged electrocardiogram may be a useful noninvasive clinical tool for the identification of electrical instability associated with paroxysmal AF in hyperthyroid patients.

Entities:  

Mesh:

Year:  1996        PMID: 8607406     DOI: 10.1016/s0002-9149(97)89391-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Circadian behavior of P-wave duration, P-wave area, and PR interval in healthy subjects.

Authors:  P E Dilaveris; P Färbom; V Batchvarov; A Ghuran; M Malik
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-04       Impact factor: 1.468

2.  P-wave dispersion in endogenous and exogenous subclinical hyperthyroidism.

Authors:  R Gen; E Akbay; A Camsari; T Ozcan
Journal:  J Endocrinol Invest       Date:  2009-07-28       Impact factor: 4.256

3.  Evaluation of the relationship between atrial septal aneurysm and cardiac arrhythmias via P-wave dispersion and signal-averaged P-wave duration.

Authors:  Onur Sinan Deveci; Kudret Aytemir; Sercan Okutucu; Erol Tulumen; Hakan Aksoy; Ergun Baris Kaya; Banu Evranos; Giray Kabakci; Lale Tokgozoglu; Ali Oto; Hilmi Ozkutlu
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

4.  Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration.

Authors:  F Cecchi; A Montereggi; I Olivotto; P Marconi; A Dolara; B J Maron
Journal:  Heart       Date:  1997-07       Impact factor: 5.994

5.  Advanced glycation end products (AGEs) and its receptors in the pathogenesis of hyperthyroidism.

Authors:  Gudrun Caspar-Bell; Indu Dhar; Kailash Prasad
Journal:  Mol Cell Biochem       Date:  2016-02-19       Impact factor: 3.396

6.  Optimal P-wave duration for bedside diagnosis of interatrial block.

Authors:  Vignendra Ariyarajah; Sirin Apiyasawat; David H Spodick
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-07       Impact factor: 1.468

7.  Utilization of Electrocardiographic P-wave Duration for AV Interval Optimization in Dual-Chamber Pacemakers.

Authors:  Dan Sorajja; Mayurkumar D Bhakta; Luis Rp Scott; Gregory T Altemose; Komandoor Srivathsan
Journal:  Indian Pacing Electrophysiol J       Date:  2010-09-05

8.  Triad of palpitation, angina, and murmur in a non-cardiac patient.

Authors:  Kanupriya Arora; Prasan K Panda
Journal:  J Family Med Prim Care       Date:  2021-11-05

Review 9.  Interatrial block: a virtual pandemic requiring attention.

Authors:  Raman Mehrzad; David H Spodick
Journal:  Iran J Med Sci       Date:  2014-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.